ERIN PETRUSIC: Open Payments
NPI 1124432497 · CHICAGO, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$146,646 in 234 payments from 12 companies in 2025. Trend: 2023 $121,438 · 2024 $88,095 · 2025 $146,646
Speaker / faculty: $116,261Consulting: $14,300Travel & lodging: $10,852Food & beverage: $5,217Education: $17
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 153 | $139,575 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 17 | $4,418 |
| E.R. Squibb & Sons, L.L.C. | 16 | $1,260 |
| ABBVIE INC. | 10 | $284 |
| Vanda Pharmaceuticals Inc. | 9 | $264 |
| Alkermes, Inc. | 6 | $260 |
| Teva Pharmaceuticals USA, Inc. | 6 | $207 |
| Lundbeck LLC | 7 | $142 |
| Axsome Therapeutics, Inc. | 3 | $84 |
| Noven Therapeutics, LLC | 4 | $64 |
Products named: INGREZZA, CAPLYTA, COBENFY, VRAYLAR, FANAPT, AUSTEDO XR, ARISTADA, LYBALVI.
Industry payments across IL — which companies pay providers there.
